Dose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials
نویسندگان
چکیده
منابع مشابه
Dose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials
Background. Absent adaptive, individualized dose-finding in early-phase oncology trials, subsequent 'confirmatory' Phase III trials risk suboptimal dosing, with resulting loss of statistical power and reduced probability of technical success for the investigational therapy. While progress has been made toward explicitly adaptive dose-finding and quantitative modeling of dose-response relationsh...
متن کاملPulmonary carcinogenicity of inhaled particles and the maximum tolerated dose.
Chronic inhalation bioassays in rodents are used to assess pulmonary carcinogenicity for purposes of hazard identification and potentially for risk characterization. The influence of high experimental doses on tumor development has been recognized for some time and has led to the concept of maximum tolerated dose (MTD) for dose selection, with the highest dose being at the MTD. Exposure at the ...
متن کاملEstablish the Maximum Tolerated Dose in Phase-I Trials using 3+3 Method
The main goal of Phase-I cancer clinical trials is to find the maximum tolerated dose (MTD) of a drug for Phase-II trial for a specific mode of administration. In Phase-I trials there is a critical need to establish MTD by using minimum possible number of patients so as to avoid exposing too many patients to sub-therapeutic doses while preserving safety and maintaining rapid accrual. 3+3 is a p...
متن کاملLiposomal cisplatin dose escalation for determining the maximum tolerated dose and dose-limiting toxicity: a phase I study.
BACKGROUND The aim of the present trial was to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of liposomal cisplatin (lipoplatin) using nephrotoxicity, gastrointestinal toxicity and myelotoxicity as the main adverse reactions. PATIENTS AND METHODS Lipoplatin, a liposomal formulation of cisplatin was first tested as monotherapy starting at a dose of 125 mg/m(2) and...
متن کاملBayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship
BACKGROUND For many molecularly targeted agents, the probability of response may be assumed to either increase or increase and then plateau in the tested dose range. Therefore, identifying the maximum effective dose, defined as the lowest dose that achieves a pre-specified target response and beyond which improvement in the response is unlikely, becomes increasingly important. Recently, a class...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: F1000Research
سال: 2017
ISSN: 2046-1402
DOI: 10.12688/f1000research.10624.3